AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04334824 — intervention group
Intervention type: DRUG
Intervention: Hydrochlorothiazide
Description: Exposure to hydrochlorothiazide will be defined as a prescription for hydrochlorothiazide alone or in combination with non-ACE inhibitor antihypertensive drugs at cohort entry date.
Study NCT04334824 — intervention group
Intervention type: DRUG
Intervention: Angiotensin-converting enzyme (ACE) inhibitors
Description: Exposure to ACE inhibitors will be defined as a prescription for an ACE inhibitor alone or in combination with non-hydrochlorothiazide antihypertensive drugs at cohort entry date.
Study NCT04876521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amisulpride
Description: low dose of Amisulpride at 100-300 mg/day
Study NCT04876521 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine-Fluoxetine Combination
Description: Olanzapine (5-10 mg/day) and Fluoxetine (20 mg/day)
Study NCT03901755 — intervention group
Intervention type: DRUG
Intervention: Alprolix
Description: Extended half-life factor IX product
Study NCT04318678 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: CD123-CAR T
Description: To treat relapsed/refractory CD123+ AML/MDS, B-ALL, T-ALL or BPDCN patient population that needs new cancer-directed therapies.
Study NCT04318678 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide
Description: Cyclophosphamide is a nitrogen mustard derivative. It acts as an alkylating agent that causes cross-linking of DNA strands by binding with nucleic acids and other intracellular structures, thus interfering with the normal function of DNA.
Study NCT04318678 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Fludarabine
Description: Fludarabine phosphate is a synthetic purine nucleoside analog. It acts by inhibiting DNA polymerase, ribonucleotide reductase and DNA primase by competing with the physiologic substrate, deoxyadenosine triphosphate, resulting in inhibition of DNA synthesis
Study NCT04318678 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Mesna
Description: Mesna is a synthetic sulfhydryl (thiol) compound. Mesna contains free sulfhydryl groups that interact chemically with urotoxic metabolites of oxaza-phosphorine derivatives such as cyclophosphamide and ifosfamide
Study NCT04318678 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Rituximab
Description: Rituximab is a monoclonal antibody directed against the CD20 antigen on the surface of B-lymphocytes
Study NCT03845205 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated AUD Treatment
Description: IAT will include computer-delivered BI in the hospital, nurse-delivered alcohol monitoring counseling at each outpatient LT follow-up visit, and at-home participation in web-based, 7-session CBT4CBT, supplemented by tailored text messages.
Study NCT03771716 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: African Dance
Description: Basic principles and guidelines for exercise programming will be followed including adequate warm-up and cool-down, progressive and gradual increments in duration, and instruction regarding avoidance of physical activity (PA) related injury. The African dance group will receive moderate intensity dance 1 hour per day, twice per week, for 6 months. The prescribed intensity will begin at light to moderate and progress to a moderate to high intensity level. Frequent assessment of heart rate and ratings of perceived exertion will ensure appropriate levels of intensity during each dance session. Levels of exertion during the dance will be prescribed and monitored based on baseline assessments of heart rate and cardiorespiratory fitness.
Study NCT03771716 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: African Cultural Immersion
Description: The Culture group will participate in activities, including cooking, art and games, music, traditional crafts, and lectures and discussions about other aspects of Africana culture and customs. Topics will vary from session to session to maintain interest and engagement. The sessions will be held in a small group format and will be lead my personnel with training in each topic. Participants will meet 1 hour per day, 3 times per week, for 6 months.
Study NCT04017546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYC065
Description: intravenous infusion
Study NCT04017546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: oral capsule
Study NCT04156087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab 50 MG/ML
Description: Combination of Durvalumab (fixed dose of 1500 mg) and Tremelimumab (fixed dose of 75 mg) will be given 2 weeks before surgery.~Minimally invasive surgical microwave ablation (MIS-MWA) of the pancreatic tumor will be performed two weeks after the first dose of Durvalumab and Tremelimumab After 4 doses of Durvalumab and Tremelimumab, only Durvalumab 1500mg is provided q4w until disease progression.~Systemic gemcitabine will be started 6 weeks after MIS-MWA. Gemcitabine will be given at a dose of 1000 mg /m² body surface, once a week for 3 weeks, followed with a week of rest.
Study NCT04156087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Combination of Durvalumab (fixed dose of 1500 mg) and Tremelimumab (fixed dose of 75 mg) will be given 2 weeks before surgery.~Minimally invasive surgical microwave ablation (MIS-MWA) of the pancreatic tumor will be performed two weeks after the first dose of Durvalumab and Tremelimumab After 4 doses of Durvalumab and Tremelimumab, only Durvalumab 1500mg is provided q4w until disease progression.~Systemic gemcitabine will be started 6 weeks after MIS-MWA. Gemcitabine will be given at a dose of 1000 mg /m² body surface, once a week for 3 weeks, followed with a week of rest.
Study NCT04156087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Combination of Durvalumab (fixed dose of 1500 mg) and Tremelimumab (fixed dose of 75 mg) will be given 2 weeks before surgery.~Minimally invasive surgical microwave ablation (MIS-MWA) of the pancreatic tumor will be performed two weeks after the first dose of Durvalumab and Tremelimumab After 4 doses of Durvalumab and Tremelimumab, only Durvalumab 1500mg is provided q4w until disease progression.~Systemic gemcitabine will be started 6 weeks after MIS-MWA. Gemcitabine will be given at a dose of 1000 mg /m² body surface, once a week for 3 weeks, followed with a week of rest.
Study NCT04156087 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally Invasive Surgical Microwave Ablation (MIS-MWA)
Description: Minimally invasive surgical microwave ablation (MIS-MWA) of the pancreatic tumor will be performed two weeks after the first dose of Durvalumab and Tremelimumab
Study NCT03951103 — intervention group
Intervention type: OTHER
Intervention: rFVIIIFc
Description: Drug according to prescription
Study NCT02610855 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Fusion Surgery
Description: Participants with severe scoliosis curves requiring spinal fusion surgery.
Study NCT02610855 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bracing
Description: Participants with scoliosis curves that require brace treatment for at least the next year. Braces include monitors to record hours of brace wear, as is current standard of care.
Study NCT02610855 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tri-axial Accelerometers
Description: Four monitors are place on the participant (waist, thigh, both ankles), attached with straps. Periods of static and dynamic activity are measured based on accelerations in three orthogonal directions for 4 day's time while participating in regular daily activities.
Study NCT02610855 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Tri-axial Accelerometers
Description: Four monitors are place on the participant (waist, thigh, both ankles), attached with straps. Periods of static and dynamic activity are measured based on accelerations in three orthogonal directions for 4 day's time while participating in regular daily activities.
Study NCT02610855 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Shear Wave Elastography (SWUE)
Description: SWUE is an ultrasound technique for noninvasively evaluating the mechanical properties (stiffness) of skeletal muscle tissue. A commercial ultrasound scanner (Aixplorer from Supersonic Imagine, France) with 2D real time SWUE will be used. The Aixplorer uses ultrasonic push beams to produce shear waves in tissue. The shear wave propagation speed is inherently related to tissue mechanical properties and is used to create a quantitative 2D elastogram of the tissue.
Study NCT02610855 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Shear Wave Elastography (SWUE)
Description: SWUE is an ultrasound technique for noninvasively evaluating the mechanical properties (stiffness) of skeletal muscle tissue. A commercial ultrasound scanner (Aixplorer from Supersonic Imagine, France) with 2D real time SWUE will be used. The Aixplorer uses ultrasonic push beams to produce shear waves in tissue. The shear wave propagation speed is inherently related to tissue mechanical properties and is used to create a quantitative 2D elastogram of the tissue.
Study NCT04895891 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EOS hand imaging
Description: For each patient, EOS images are compared with CT images
Study NCT05033171 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: EOS 2D/3D scanning
Description: EOS Micro Dose imaging will be done on the third day after surgery, on the third, the sixth, the twelfth and twenty fourth month after surgery.
Study NCT03418948 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CC followed by EC
Description: CC = conventional colonoscopy EC = endocuff assisted colonoscopy
Study NCT03418948 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EC followed by CC
Description: CC = conventional colonoscopy EC = endocuff assisted colonoscopy
Study NCT03418948 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 2x EC
Description: EC = endocuff assisted colonoscopy
Study NCT03418948 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 2x CC
Description: CC = conventional colonoscopy
Study NCT03448926 — intervention group
Intervention type: OTHER
Intervention: Treatment Recommendation Surveys
Description: Treatment Recommendation Surveys are completed by the treating physicians before and after receiving results from the DCISionRT test, which is prognostic for risk of recurrence over 10 years and predictive for benefit from radiation therapy.
Study NCT03448926 — intervention group
Intervention type: DEVICE
Intervention: 7-gene biosignature
Description: Ordering the 7-gene biosignature assay (DCISionRT) as a part of routine care for DCIS is a prerequisite (inclusion criterion) for the study. The study is not designed to determine the efficacy of the assay, rather it is designed to meausre the impact of the assay results on treatment decisions for patients with DCIS.
Study NCT00651742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: All participants received S-1 orally at a dose of 30 mg/m2 BID for 14 days followed by a 1-week recovery period, repeated every 3 weeks. The trial was planned to proceed to the second stage only if sufficient efficacy was demonstrated in Stage 1.
Study NCT04398433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INO-3107
Description: INO-3107 administered by IM injection followed by EP using CELLECTRA™ 2000 device at Day 0, Week 3, 6, and 9.
Study NCT04398433 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CELLECTRA™ 2000
Description: CELLECTRA™ 2000 device used for EP following IM delivery of INO-3107.
Study NCT01074970 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 75 mg/m2 IV infusion over 60 minutes, D1 every 21 days for 4 cycles
Study NCT01074970 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rucaparib
Description: Rucaparib 24mg C1,30mg C2-4, D1,2,3 every 21 days for 4 cycles
Study NCT00509977 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Light Treatment
Description: Light treatment applied to half of the face at each study visit
Study NCT00509977 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser Treatment
Description: Laser treatment applied to half of the face at each study visit
Study NCT04265144 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: 62 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation
Study NCT04265144 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Skin biopsies only for volunteers among patients
Study NCT04265144 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bronchoalveolar samples
Description: 50 ml of bronchoalveolar samples if pulmonary flare requires this type of exploration only for volunteers among patients
Study NCT04265144 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Digestives biopsies if requires this type of exploration in the standard of care only for volunteers among patients
Study NCT01873222 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OFDI-guided PCI & IVUS
Description: * Assessment by IVUS at post-PCI~* Assessment by OFDI at a 8-month follow-up
Study NCT01873222 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IVUS-guided PCI & OFDI
Description: * Assessment by OFDI at post-PCI~* Assessment by OFDI at a 8-month follow-up
Study NCT02202005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine
Description: Nevirapine 400mg PR tablet
Study NCT04047602 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Reduced Dose SRS
Description: Subjects will receive SRS treatment at a reduced dose based on the brain tumor size
Study NCT01648751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaginal estrogen
Description: 1 gram vaginally for 7 days, followed by 1 gram vaginally twice weekly thereafter
Study NCT01648751 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 gram vaginally for 7 days, followed by 1 gram vaginally twice weekly thereafter
Study NCT02601612 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: D46cpΔM2-2 vaccine
Description: Delivered as nose drops
Study NCT02601612 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Delivered as nose drops
Study NCT02852655 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MK-3475
Study NCT02852655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3475
Study NCT03361761 — intervention group
Intervention type: OTHER
Intervention: Health education program
Description: formalized/official Health education program
Study NCT03361761 — intervention group
Intervention type: OTHER
Intervention: Health education program
Description: non formalized/official Health education program
Study NCT03818854 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Mesenchymal Stromal Cells
Description: Immediately prior to administration, the study product will be thawed and diluted 1:1 with reconstitution media (1:1 mix of 5% human serum albumin and 10% Dextran 40). Additional reconstitution media is added to a final product volume of 300 mL.
Study NCT03818854 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cell Reconstitution Media
Description: 300 mL of reconstitution media (1:1 mix of 5% human serum albumin and 10% Dextran 40)
Study NCT03970746 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PDC*lung01
Description: PDC\*lung01 includes, in similar proportion, seven active agents, made of irradiated human plasmacytoid dendritic cells (PDC) loaded separately with a distinct synthetic peptide encoded by a lung tumor antigen, namely NY-ESO-1, MAGE-A3, MAGEA4, Multi-MAGE (an epitope common to several MAGE-A antigens), SURVIVN, MUC1 or a peptide derived from the Melan-A antigen.
Study NCT02202005 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nevirapine
Description: Nevirapine 400mg PR tablet
Study NCT02202005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Viramune®
Description: Viramune® 400 mg Retardtabletten
Study NCT03970746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Keytruda Injectable Product
Description: The intention and decision to prescribe the anti-PD-1 monotherapy as SoC (TPS≥50%) must have been made by the investigator before and regardless of the patient's participation in the study.
Study NCT02202005 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Viramune®
Description: Viramune® 400 mg Retardtabletten
Study NCT00326404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desogestrel-Ethinyl Estradiol 21 tablets
Description: The participants in the continuous study arm will be given 4 packs of Marvelon-21, so that they can take the pills continuously for 84 days followed by no medication for 7 days. During these 7 days, the participant will have a withdrawal bleed. This sequence is repeated by the participant for a total of 12 months. Each patient in the continuous arm will have 4 withdrawal bleeds per year.
Study NCT00326404 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desogestrel-Ethinyl Estradiol 28 tablets
Description: The participants in the cyclical arm of the study will be given 3 packs of Marvelon-28 and asked to take all the pills in the packet, including the placebo pills. During the week of placebo pills, these participants will have a withdrawal bleed. Each patient in the cyclical arm will have 12 withdrawal bleeds per year. The duration of study drug treatment for both arms is 12 months.
Study NCT05412797 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cycling/Using a DeskCycle
Description: The intervention was conducted in two phases. In phase 1, the intervention group were given the DeskCycles to use for 8 weeks. In phase, the control group from phase 1 were given the DeskCycles to use. Intervention group from phase 1 became controls in phase 2
Study NCT05412797 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Regular activities
Description: The active comparator performed normal daily activities
Study NCT04602221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Description: Tablet
Study NCT03970746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alimta Injectable Product
Description: For patients with non-squamous NSCLC included in Cohorts A1 and A2, maintenance by pemetrexed (IV every 3 weeks) can be administered according to SoC.
Study NCT01967238 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IM Pneumococcal, meningococcal, or flu vaccine
Description: Volunteers given one of the 3 vaccines
Study NCT04421820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOLD-100 in combination with FOLFOX Chemotherapy (Dose Expansion)
Description: 625 mg/m2 IV over 30 minutes, q2weeks
Study NCT04421820 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BOLD-100 in combination with FOLFOX Chemotherapy (Dose Expansion)
Description: 625 mg/m2 IV over 30 minutes, q2weeks
Study NCT04421820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOLD-100 in combination with FOLFOX Chemotherapy (Dose Escalation)
Description: 320 mg/m2 IV over 30 minutes, q2weeks; 420 mg/m2 IV over 30 minutes, q2weeks; 500 mg/m2 IV over 30 minutes, q2weeks; 625 mg/m2 IV over 30 minutes, q2weeks
Study NCT04163341 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapted Common Elements Treatment Approach
Description: The intervention is a transdiagnostic cognitive behavioral therapy approach to treating any combination of depression, anxiety, post-traumatic stress, or substance use disorder that has been adapted the needs of adults with HIV and to additionally address HIV care engagement.
Study NCT04602221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306
Description: Film-coated tablet
Study NCT01967849 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Oral Glucose tolerance test
Study NCT04115761 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: autologous dendritic cells
Description: The total 10 doses (1 mL/dose; 2±0.5 × 10\^7 cell/dose) of ADCV01 will be administered to patients assigned to the investigational group. The ADCV01 will be administered to the bilateral subaxillary subcutaneous regional lymph nodes (half of volume about 0.5 mL of ADCV01) once weekly for the first 4 doses, and the following 2 treatments will be administered bi-weekly. The last 4 treatments will be administered every 4 weeks.
Study NCT06595251 — intervention group
Intervention type: OTHER
Intervention: Fit2Play curriculum
Description: Fit2Play is a daily after-school park-based program (Monday-Friday, 2 PM-6 PM) that comprises (1) 60 minutes of physical activity that incorporates multiple sports (soccer, kickball, flag football) and activities from Sports, Play and Active Recreation for Kids (SPARK), a play- and evidenced-based, outcome-oriented, structured, active recreation program for children with a focus on developing and improving motor skills, movement knowledge, social and personal skills; and (2) 20-30 minutes of nutrition education lessons 1-2 times per week that incorporate EmpowerMe4Life, a health and wellness curriculum aligned to the National Health Education Standards for fifth grade and grounded in the American Heart Association's scientific recommendations in promoting heart-healthy lifestyles. Miami-Dade Parks and Recreation is the sponsor of the Fit2Play prospective cohort study. Duke is conducting a secondary data analysis on data collected as part of the Fit2Play study.
Study NCT06593015 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Radiological tool for the diagnosis of myosteatosis
Description: Calculation of muscle attenuation at L3 CT scan for each patients and evaluation of the relationship between muscle attenuation values and survival